Viking Therapeutics Shares Face Mounting Pressure Amid Clinical and Financial Setbacks

Viking Therapeutics finds itself navigating turbulent waters as its stock experiences a pronounced downward trajectory. Investor confidence has been significantly undermined by disappointing trial outcomes for a key drug candidate and a rapidly deteriorating financial position, firmly establishing the stock within a bearish trend.

Financial Strain Intensifies

The company’s financial health shows alarming signs of distress, compounding existing challenges. Recent figures reveal a substantial widening of losses, with the GAAP net loss for Q2 2025 reaching $65.6 million. This represents a dramatic increase compared to the $22.3 million loss reported during the same quarter last year. Market experts have responded by significantly revising their loss-per-share estimates upward for the 2025 fiscal year over the past two months.

Adding to market unease, CEO Brian Lian recently executed notable sales of his company stock holdings—a move closely watched and often interpreted as a lack of confidence by market participants. These shrinking financial reserves leave minimal flexibility for ongoing research and development initiatives.

Oral Obesity Drug Trial Disappoints

The primary catalyst for the recent share price decline stems from underwhelming Phase 2 study results for VK2735, Viking’s oral medication for weight management. While the treatment demonstrated efficacy by achieving up to 12.2% weight loss after 13 weeks, this success was entirely overshadowed by significant tolerability issues.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

The data reveals substantial patient discontinuation rates, with approximately 28% of all trial participants stopping treatment prematurely. Particularly concerning is that 20% of patients withdrew specifically due to adverse side effects—a rate substantially higher than observed in the placebo control group. The majority of these side effects were gastrointestinal in nature, characterized by high incidence rates of nausea and vomiting.

Technical Indicators Confirm Bearish Momentum

The stock’s price action reflects these fundamental concerns, with technical analysis confirming the persistent negative momentum. Both the 50-day and 200-day moving averages underscore a clear and established downtrend that has developed over recent months. Viking’s shares have significantly underperformed relative to sector peers and have recorded substantial losses throughout the past year.

The convergence of clinical setbacks and financial pressures creates a challenging environment for Viking Therapeutics, with limited apparent catalysts to reverse the current negative sentiment surrounding the stock.